vs
Side-by-side financial comparison of Pacira BioSciences, Inc. (PCRX) and VARONIS SYSTEMS INC (VRNS). Click either name above to swap in a different company.
Pacira BioSciences, Inc. is the larger business by last-quarter revenue ($177.4M vs $173.1M, roughly 1.0× VARONIS SYSTEMS INC). On growth, VARONIS SYSTEMS INC posted the faster year-over-year revenue change (26.9% vs 5.0%). Over the past eight quarters, VARONIS SYSTEMS INC's revenue compounded faster (15.2% CAGR vs -0.2%).
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
Varonis Systems, Inc. is a software company based in Miami, Florida with R&D offices in Herzliya, Israel. The company’s Data Security Platform analyzes data and data activity using the insights to identify data exposure risks stemming from access permissions and software-as-a-service (SaaS) app configurations, triggering automated remediation capabilities in response.
PCRX vs VRNS — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $177.4M | $173.1M |
| Net Profit | $2.9M | — |
| Gross Margin | — | 76.0% |
| Operating Margin | 3.9% | -1.7% |
| Net Margin | 1.6% | — |
| Revenue YoY | 5.0% | 26.9% |
| Net Profit YoY | — | — |
| EPS (diluted) | $0.07 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $177.4M | $173.1M | ||
| Q4 25 | $196.9M | $173.4M | ||
| Q3 25 | $179.5M | $161.6M | ||
| Q2 25 | $181.1M | $152.2M | ||
| Q1 25 | $168.9M | $136.4M | ||
| Q4 24 | $187.3M | $158.5M | ||
| Q3 24 | $168.6M | $148.1M | ||
| Q2 24 | $178.0M | $130.3M |
| Q1 26 | $2.9M | — | ||
| Q4 25 | — | $-27.8M | ||
| Q3 25 | $5.4M | $-29.9M | ||
| Q2 25 | $-4.8M | $-35.8M | ||
| Q1 25 | $4.8M | $-35.8M | ||
| Q4 24 | — | $-13.0M | ||
| Q3 24 | $-143.5M | $-18.3M | ||
| Q2 24 | $18.9M | $-23.9M |
| Q1 26 | — | 76.0% | ||
| Q4 25 | 79.5% | 78.9% | ||
| Q3 25 | 80.9% | 78.2% | ||
| Q2 25 | 77.4% | 79.5% | ||
| Q1 25 | 79.7% | 78.7% | ||
| Q4 24 | 78.7% | 83.6% | ||
| Q3 24 | 76.9% | 83.8% | ||
| Q2 24 | 75.1% | 82.8% |
| Q1 26 | 3.9% | -1.7% | ||
| Q4 25 | 1.2% | -17.5% | ||
| Q3 25 | 3.5% | -22.2% | ||
| Q2 25 | 4.7% | -24.0% | ||
| Q1 25 | 1.2% | -32.1% | ||
| Q4 24 | 13.2% | -11.1% | ||
| Q3 24 | -82.8% | -16.0% | ||
| Q2 24 | 15.9% | -22.1% |
| Q1 26 | 1.6% | — | ||
| Q4 25 | — | -16.0% | ||
| Q3 25 | 3.0% | -18.5% | ||
| Q2 25 | -2.7% | -23.5% | ||
| Q1 25 | 2.8% | -26.2% | ||
| Q4 24 | — | -8.2% | ||
| Q3 24 | -85.1% | -12.4% | ||
| Q2 24 | 10.6% | -18.4% |
| Q1 26 | $0.07 | — | ||
| Q4 25 | $0.05 | $-0.23 | ||
| Q3 25 | $0.12 | $-0.26 | ||
| Q2 25 | $-0.11 | $-0.32 | ||
| Q1 25 | $0.10 | $-0.32 | ||
| Q4 24 | $0.38 | $-0.12 | ||
| Q3 24 | $-3.11 | $-0.16 | ||
| Q2 24 | $0.39 | $-0.21 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $144.3M | $179.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $653.9M | $453.5M |
| Total Assets | $1.2B | $1.6B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $144.3M | $179.3M | ||
| Q4 25 | $238.4M | $883.7M | ||
| Q3 25 | $246.3M | $671.3M | ||
| Q2 25 | $445.9M | $770.9M | ||
| Q1 25 | $493.6M | $567.6M | ||
| Q4 24 | $484.6M | $529.0M | ||
| Q3 24 | $453.8M | $844.8M | ||
| Q2 24 | $404.2M | $582.5M |
| Q1 26 | — | — | ||
| Q4 25 | $372.2M | — | ||
| Q3 25 | $376.7M | — | ||
| Q2 25 | $580.5M | — | ||
| Q1 25 | $583.4M | — | ||
| Q4 24 | $585.3M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | $653.9M | $453.5M | ||
| Q4 25 | $693.1M | $598.7M | ||
| Q3 25 | $727.2M | $604.8M | ||
| Q2 25 | $757.8M | $341.5M | ||
| Q1 25 | $798.5M | $367.7M | ||
| Q4 24 | $778.3M | $455.7M | ||
| Q3 24 | $749.6M | $428.6M | ||
| Q2 24 | $879.3M | $458.6M |
| Q1 26 | $1.2B | $1.6B | ||
| Q4 25 | $1.3B | $1.8B | ||
| Q3 25 | $1.3B | $1.7B | ||
| Q2 25 | $1.5B | $1.6B | ||
| Q1 25 | $1.6B | $1.6B | ||
| Q4 24 | $1.6B | $1.7B | ||
| Q3 24 | $1.5B | $1.5B | ||
| Q2 24 | $1.6B | $1.1B |
| Q1 26 | — | — | ||
| Q4 25 | 0.54× | — | ||
| Q3 25 | 0.52× | — | ||
| Q2 25 | 0.77× | — | ||
| Q1 25 | 0.73× | — | ||
| Q4 24 | 0.75× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $55.0M |
| Free Cash FlowOCF − Capex | — | $49.0M |
| FCF MarginFCF / Revenue | — | 28.3% |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $118.2M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $55.0M | ||
| Q4 25 | $43.7M | $24.7M | ||
| Q3 25 | $60.8M | $33.4M | ||
| Q2 25 | $12.0M | $21.3M | ||
| Q1 25 | $35.5M | $68.0M | ||
| Q4 24 | $33.1M | $24.3M | ||
| Q3 24 | $53.9M | $22.5M | ||
| Q2 24 | $53.2M | $11.7M |
| Q1 26 | — | $49.0M | ||
| Q4 25 | $43.5M | $20.7M | ||
| Q3 25 | $57.0M | $30.4M | ||
| Q2 25 | $9.3M | $18.0M | ||
| Q1 25 | $26.9M | $65.7M | ||
| Q4 24 | $31.0M | $19.9M | ||
| Q3 24 | $49.8M | $21.3M | ||
| Q2 24 | $51.6M | $10.9M |
| Q1 26 | — | 28.3% | ||
| Q4 25 | 22.1% | 12.0% | ||
| Q3 25 | 31.7% | 18.8% | ||
| Q2 25 | 5.1% | 11.8% | ||
| Q1 25 | 15.9% | 48.1% | ||
| Q4 24 | 16.6% | 12.6% | ||
| Q3 24 | 29.6% | 14.4% | ||
| Q2 24 | 29.0% | 8.4% |
| Q1 26 | — | — | ||
| Q4 25 | 0.1% | 2.3% | ||
| Q3 25 | 2.2% | 1.8% | ||
| Q2 25 | 1.5% | 2.2% | ||
| Q1 25 | 5.1% | 1.7% | ||
| Q4 24 | 1.1% | 2.7% | ||
| Q3 24 | 2.4% | 0.8% | ||
| Q2 24 | 0.9% | 0.6% |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 11.20× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 7.37× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 2.82× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
VRNS
| SaaS | $161.1M | 93% |
| Term license subscriptions | $6.9M | 4% |
| Maintenance and services | $5.2M | 3% |
